We have also shown that inhibition of ATX, using a type IV inhibitor Cpd17, ameliorates fibrosis, inflammation, and steatosis in HSCs and macrophages in vitro, as well as in NASH and liver cirrhosis mouse models. Here, ENPP2 is linked to metabolic dysfunction-associated steatohepatitis.